1.1)Medical School, Kunming University of Science and Technology, Kunming 650500, China;2.2)General Surgery Department 1, The First People’s Hospital of Yunnan Province, Kunming 650032, China
R73-36+2;R392.12
This work was supported by grants from Yunnan Health Training Project of Reserve Talents (H-2019037), Doctoral Research Foundation of Yunnan First People’s Hospital (KHBS-2020-022), Yunnan Fundamental Research Projects (2019FD015), and Kunming Joint Special Project on Medical Research (2019FE001-310).
Chimeric antigen receptor T cells (CAR-T) have achieved remarkable success in the treatment of hematological cancers, but little progress in solid tumors. Meanwhile, innate immune cells-based tumor immunotherapy has been scarcely developed. Macrophages detect and clear malignant cells through phagocytosis and innate immune sensing, thus being potential targets for cancer immunotherapy. Promising evidence from preclinical studies have shown chimeric antigen receptor macrophages (CAR-M) as an effective therapeutic strategy in solid tumors. This review sketches the prospect of CAR-immune cell therapeutics and emphasizes current status and perspective of CAR-M cell therapy trials and limitations associated with CAR-M. We also describe CAR-M can be manufactured from pre-existing cell lines or induced pluripotent stem cells, while transfection vectors for CAR-M show different characteristics, highlighting CAR-M as a next-generation therapeutic modality linking the closely intertwined innate and adaptive immunity to induce efficacious anti-tumor immune responses.
YANG Yan, GAN Ni-Cui, PENG Ning-Xin, ZHANG Lan-Xuan, ZHANG Ji-Hong, LI Jin-Yuan. CAR-M Cell-based Immunotherapy Directed Against Solid Tumors[J]. Progress in Biochemistry and Biophysics,2023,50(7):1553-1559
Copy® 2024 All Rights Reserved ICP:京ICP备05023138号-1 京公网安备 11010502031771号